Impact Of Diabetes Mellitus Type 2 On Pacing Parameters In Patients With Implantation Of Permanent Pacemaker

Objective: To observe the impact of diabetes mellitus on pacing parameters in patients with implantation of permanent pacemaker.Methods: January 2010 to March 2014 at the First Hospital of Lanzhou University Heart Center Cardiac permanent pacemaker implantation in patients(mainly dual chamber pacemaker), a total of 214 cases, in accordance with pre-defined data collection forms to collect information about selected candidates, and after two corrections to ensure the collection of the information is correct, mainly collect data read by the pacemaker cases and follow-up data and other means. Pacing parameters were compared for the two groups. The main application of the two sets of data SPSS19.0 statistical software for statistical analysis.Results: The clinical data were compared when two groups in age, gender, coronary heart disease, hypertension, hyperlipidemia, and SSS, AVB number of aspects, there was no significant difference((P>0.05), but the DM group glycated hemoglobin(HbAlc) was significantly higher than the non-DM group, statistically significant differences(P<0.05). Between the two groups in patients with atrial and ventricular pacing threshold, sensing the impedance difference was not statistically significant(P baseline>0.05). Surgery after 1, 3, 6 months and 1 year pacing parameter testing, after 1 year, corresponding to compare two sets of data, the DM group VS non-DM group, 1. Atrial pacing threshold in 1 month(0.53±0.29)V ratio(0.47±0.17)V, in 3 months(0.51±0.21)V ratio(0.46±0.31)V, in 6 months(0.49±0.17)V ratio(0.47±0.16)V, in 12 months(0.53±0.40)V ratio(0.50±0.17)V, 24 months(0.54±0.60)V ratio(0.51±0.19)V, 36 months(0.56±0.19)V ratio(0.52±0.20)V, 48 months(0.57±0.13)V ratio(0.55±0.18)V comparison; 2. Atrial sensing in 1 month(2.96±1.29)mV ratio(2.90±1.37)mV, in 3 months(2.91±1.18)mV ratio(2.85±1.39)mV, in 6 months(3.63±1.53)mV ratio(3.02±1.07)mV, in 12 months(2.84±1.12)mV ratio(2.83±1.38)mV, 24 months(2.88±1.19)mV ratio(2.69±1.39)mV, 36 months(2.99±1.44)mV ratio(2.96±1.49)mV, 48 months(2.86±1.02)mV ratio(2.39±1.29)mV comparison; 3. Atrial impedance 1 month(518.77±174.53)Ω ratio(529.22±132.77)Ω, 3 months(508.45±154.71)Ω ratio(531.89±151.36)Ω,in 6 months(501.93±149.54)Ω ratio(526.91±146.45)Ω, in 12 months(512.05±145.72)Ω ratio(518.30±143.60)Ω, 24 months(526.89±180.87)Ω ratio(567.96±194.50)Ω, 36 months(616.60± 160.05)Ω ratio(519.92±143.77)Ω, 48 months(728.17±139.39)Ω ratio(508.78±155.43)Ω comparison; 4. Ventricular pacing threshold in 1 month(0.68±0.63)V ratio(0.66±0.73)V, 3 months(0.64±0.35)V ratio(0.61±0.28)V, 6 months(0.67±0.30)V ratio(0.64±0.24)V, 12 months(0.69±0.35)V ratio(0.67±0.24)V, 24 months(0.74±0.38)V ratio(0.69±0.22)V, 36 months(0.74± 0.42)V ratio(0.71±0.31)V, 48 months(0.84±0.42)V ratio(0.78±0.35)V; 5. Ventricular sensing 1 month(12.55±5.72)m V ratio(12.14±4.99)m V, 3 months(12.33±5.99)m V ratio(11.73±4.42)m V, 6 months(12.44±5.78)m V ratio(11.52±4.22)m V, in 12 months(12.37±5.93)m V ratio(11.39±3.86)m V, 24 months(12.16±6.21)m V ratio(10.19±4.61)m V, 36 months(12.44±6.23)m V ratio(11.46±5.35)m V, 48 months(13.91±10.55)m V than(12.53±5.07)m V comparative; 6. Ventricular impedance in 1 months(490.30±203.28)Ω ratio(509.64±201.33)Ω, 3 months(465.54 ±157.57)Ω ratio(481.88±174.08)Ω, in 6 months(444.47±112.11)Ω ratio(466.64±156.93)Ω, in 12 months(437.16±116.36)Ω ratio(448.18±147.96)Ω, 24 months(437.34±115.14)Ω ratio(442.27± 139.26)Ω, 36 months(409.46±110.11)Ω ratio(436.45±125.77)Ω, 48 months(404.93±116.15)Ω ratio(427.80±149.98)Ω; Comparison of the respective sets of data respectively, resulting in two sets of data showed no significant difference(P>0.05).Conclusion: This study longest follow-up of 4 years, during follow-up, patients with diabetes(glycated hemoglobin control between seven and eight percent) and non-diabetic group pacing parameters no significant difference.